1. Home
  2. LAZ vs ACAD Comparison

LAZ vs ACAD Comparison

Compare LAZ & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lazard Inc.

LAZ

Lazard Inc.

HOLD

Current Price

$50.34

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.87

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAZ
ACAD
Founded
1848
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.9B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
LAZ
ACAD
Price
$50.34
$21.87
Analyst Decision
Hold
Buy
Analyst Count
8
22
Target Price
$52.75
$30.55
AVG Volume (30 Days)
1.3M
1.7M
Earning Date
05-01-2026
05-06-2026
Dividend Yield
4.00%
N/A
EPS Growth
N/A
69.12
EPS
2.17
2.30
Revenue
$3,186,466,000.00
$726,437,000.00
Revenue This Year
$14.52
$18.90
Revenue Next Year
$13.08
$11.62
P/E Ratio
$23.09
$9.56
Revenue Growth
1.48
40.45
52 Week Low
$33.45
$14.08
52 Week High
$58.75
$28.35

Technical Indicators

Market Signals
Indicator
LAZ
ACAD
Relative Strength Index (RSI) 69.32 48.71
Support Level $47.92 $20.22
Resistance Level $52.41 $22.03
Average True Range (ATR) 1.93 0.73
MACD 1.37 0.11
Stochastic Oscillator 100.00 55.86

Price Performance

Historical Comparison
LAZ
ACAD

About LAZ Lazard Inc.

Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: